JP2022531141A5 - - Google Patents
Info
- Publication number
- JP2022531141A5 JP2022531141A5 JP2021563181A JP2021563181A JP2022531141A5 JP 2022531141 A5 JP2022531141 A5 JP 2022531141A5 JP 2021563181 A JP2021563181 A JP 2021563181A JP 2021563181 A JP2021563181 A JP 2021563181A JP 2022531141 A5 JP2022531141 A5 JP 2022531141A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence described
- domain containing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093134A JP2025131704A (ja) | 2019-04-24 | 2025-06-04 | 遺伝子治療のためのコンディショニング方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838278P | 2019-04-24 | 2019-04-24 | |
| US62/838,278 | 2019-04-24 | ||
| US201962944925P | 2019-12-06 | 2019-12-06 | |
| US62/944,925 | 2019-12-06 | ||
| PCT/US2020/029934 WO2020219964A1 (en) | 2019-04-24 | 2020-04-24 | Conditioning methods for gene therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093134A Division JP2025131704A (ja) | 2019-04-24 | 2025-06-04 | 遺伝子治療のためのコンディショニング方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022531141A JP2022531141A (ja) | 2022-07-06 |
| JP2022531141A5 true JP2022531141A5 (cg-RX-API-DMAC7.html) | 2023-05-02 |
Family
ID=72940803
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563181A Pending JP2022531141A (ja) | 2019-04-24 | 2020-04-24 | 遺伝子治療のコンディショニング方法 |
| JP2025093134A Pending JP2025131704A (ja) | 2019-04-24 | 2025-06-04 | 遺伝子治療のためのコンディショニング方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093134A Pending JP2025131704A (ja) | 2019-04-24 | 2025-06-04 | 遺伝子治療のためのコンディショニング方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220175946A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3958878A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022531141A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113993550A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020261079A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134689A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020219964A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| CN113330026A (zh) * | 2018-10-23 | 2021-08-31 | 美真达治疗公司 | Fc沉默的抗体药物缀合物(ADC)及其用途 |
| EP4543469A4 (en) * | 2022-06-27 | 2026-06-03 | Beam Therapeutics Inc | COMPOSITIONS AND CONDITIONING METHODS OF NON-GENOTOXIC CELLS |
| WO2024073751A1 (en) * | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| IL322368A (en) * | 2023-02-03 | 2025-09-01 | Genzyme Corp | HSC-specific antibody-conjugated lipid nanoparticles and their uses |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10111966B2 (en) * | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
| CN109641051A (zh) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | 用于耗尽细胞的组合物和方法 |
| US12485186B2 (en) * | 2017-03-31 | 2025-12-02 | The Children's Medical Center Corporation | Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation |
| CA3070242A1 (en) * | 2017-07-18 | 2019-01-24 | Calimmune, Inc. | Compositions and methods for treating beta-hemoglobinopathies |
| EP3700568A4 (en) * | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| US10882915B2 (en) * | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| US10924796B2 (en) * | 2018-04-10 | 2021-02-16 | Logitech Europe S.A. | System and methods for interactive filters in live streaming media |
| CN113330026A (zh) * | 2018-10-23 | 2021-08-31 | 美真达治疗公司 | Fc沉默的抗体药物缀合物(ADC)及其用途 |
| WO2020219778A2 (en) * | 2019-04-24 | 2020-10-29 | Magenta Therapeutics, Inc. | Anti-cd117 antibody-drug conjugates and uses thereof |
| JP2022530438A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | 抗cd117抗体薬物複合体およびその使用 |
| US20240115615A1 (en) * | 2021-02-09 | 2024-04-11 | Jasper Therapeutics, Inc. | Modified stem cell compositions and methods for use |
| EP4419114A4 (en) * | 2021-10-18 | 2025-10-15 | Jasper Therapeutics Inc | MODIFIED STEM CELL COMPOSITIONS AND METHODS OF USE THEREOF |
-
2020
- 2020-04-24 EP EP20795937.0A patent/EP3958878A4/en active Pending
- 2020-04-24 CA CA3134689A patent/CA3134689A1/en active Pending
- 2020-04-24 JP JP2021563181A patent/JP2022531141A/ja active Pending
- 2020-04-24 CN CN202080045488.3A patent/CN113993550A/zh active Pending
- 2020-04-24 WO PCT/US2020/029934 patent/WO2020219964A1/en not_active Ceased
- 2020-04-24 AU AU2020261079A patent/AU2020261079A1/en active Pending
-
2021
- 2021-10-21 US US17/507,456 patent/US20220175946A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093134A patent/JP2025131704A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023520636A5 (cg-RX-API-DMAC7.html) | ||
| JP2021500391A5 (cg-RX-API-DMAC7.html) | ||
| JP2025160215A5 (cg-RX-API-DMAC7.html) | ||
| JP2019522050A5 (cg-RX-API-DMAC7.html) | ||
| WO2019084064A4 (en) | Compositions and methods for the depletion of cd117+ cells | |
| JP2022512629A5 (cg-RX-API-DMAC7.html) | ||
| KR0135632B1 (ko) | 감염성 및 염증성 병변 표적용 항-백혈구 결합체 및 이를 함유하는 제제 및 키트 | |
| Krasniqi et al. | Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma | |
| Le Doussal et al. | Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response | |
| JP5843884B2 (ja) | 抗cd38抗体 | |
| US12371506B2 (en) | Subcutaneous administration of anti-CD38 antibodies | |
| EP4010082B2 (en) | MULTISPECIFIC TCR DELTA VARIABLE DOMAIN 1 ANTIBODIES | |
| JP2022553839A5 (cg-RX-API-DMAC7.html) | ||
| WO2019108863A4 (en) | Compositions and methods for the depletion of cd5+ cells | |
| WO2021188590A2 (en) | T-cell bispecific binding proteins | |
| SG11202110287QA (en) | Amatoxin antibody-drug conjugates and uses thereof | |
| MX2012009352A (es) | "anticuerpos cd20 y su utilización". | |
| US20240075157A1 (en) | Fc silenced antibody drug conjugates (adcs) and uses thereof | |
| US20260102505A1 (en) | Anti-cd45-ign antibody drug conjugates and uses thereof | |
| MY108519A (en) | Novel antibodies reactive with human carcinomas. | |
| JP4912153B2 (ja) | タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法 | |
| JP2024519970A (ja) | 三価放射性同位体生物標的放射性医薬品、調製方法及び使用 | |
| WO2019108860A4 (en) | Compositions and methods for the depletion of cd2+ cells | |
| US20220177577A1 (en) | Anti-cd117 antibody drug conjugates and uses thereof | |
| US20220175946A1 (en) | Conditioning methods for gene therapy |